Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis
Status:
Completed
Trial end date:
1996-09-01
Target enrollment:
Participant gender:
Summary
To determine whether gradual initiation of sulfamethoxazole/trimethoprim (SMX/TMP) reduces
the incidence of treatment-limiting adverse reactions compared to the routine initiation of
the drugs for Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV-infected patients.
Although a number of clinical trials have demonstrated the superiority of SMX/TMP for PCP
prophylaxis, the incidence of adverse reactions to this medication is high. In a pilot study
in which patients were initiated with SMX/TMP prophylaxis by gradually increasing the dose
over 2 weeks, no significant adverse reactions have occurred.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Glaxo Wellcome
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination